We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Powered Pathology to Drive Insight in Cancer Diagnosis

By LabMedica International staff writers
Posted on 25 Mar 2022
Print article
Image: Proscia and Visiopharm share insights about future of digital pathology at USCAP 2022 (Photo courtesy of Visiopharm)
Image: Proscia and Visiopharm share insights about future of digital pathology at USCAP 2022 (Photo courtesy of Visiopharm)

Driven by a growing base of evidence on the economic and clinical benefits of adoption, leading laboratories are increasingly looking to adopt AI in routine practice to optimize operations and improve patient care. Powerful computational applications have highlighted the role that AI could play in improving diagnosis for an increasingly large portion of lab volume. However, a key barrier to deriving the full value of AI is the lab’s ability to seamlessly integrate this diverse range of applications into routine operations. Now, a strategic partnership will deliver integrated AI-enabled solutions that aim to improve clinical decision making for cancer care.

Proscia (Philadelphia, PA, USA) and Visiopharm (Hoersholm, Denmark) have entered into a collaboration through which the partners will advance the use of AI-enabled solutions to deliver new insights to pathologists for two of the most common cancer diagnoses. Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Visiopharm is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support diagnostic decision making.

Proscia and Visiopharm have now joined forces to deliver a unified solution that combines Visiopharm’s suite of CE-IVD clinical AI applications – including breast IHC markers, breast metastasis detection, and colon metastasis detection – with Proscia’s CE-IVD Concentriq Dx platform for image-based data and workflow management. Users of Concentriq Dx can now leverage the full suite of Visiopharm’s AI applications directly in the routine workflow, helping pathologists quantify the expression of biomarkers aiming to accelerate treatment decisions for patient care. This marks an expansion of the companies’ existing collaboration integrating AI-enabled solutions which have successfully driven breakthroughs in translational research and advance precision medicine for life sciences companies.

“We are excited about expanding our successful partnership in the research market to include the clinical market,” said Michael Grunkin, CEO of Visiopharm. “With Visiopharm’s commitment to AI-driven Precision Pathology, and Proscia’s commitment to interoperability and digital workflow solutions for pathology labs, this integrated solution combines efficient workflows and support for optimal treatment decisions to our clinical customers.”

“Our unified solution will equip pathologists with powerful AI applications to quantify expression of biomarkers aiming to significantly improve treatment decisions,” said David West, CEO of Proscia. “Ultimately, this will enable pathologists to fully realize AI’s potential in unlocking insights that remain hidden to the human eye, helping to advance the way we understand and treat disease, driving accuracy in diagnosis, and establishing prognosis and personalized therapies for patients.”

Related Links:

Gold Supplier
COVID-19 Immune Response Test
Electrolyte Analyzer
Molecular Diagnostic System
FlashDetect Flash48
Chemistry Analyzer

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.